日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE-042 China study

帕博利珠单抗与化疗治疗中国非小细胞肺癌且程序性死亡配体1肿瘤比例评分≥1%患者的五年疗效:KEYNOTE-042中国研究

Wu, Yi-Long; Zhang, Li; Fan, Yun; Zhou, JianYing; Zhang, Li; Zhou, Qing; Li, Wei; Hu, ChengPing; Chen, GongYan; Zhang, Xin; Zhou, CaiCun; Arenas, Carmen González; Chen, Zhenghong; Yu, Wen Cheng; Mok, Tony S K

Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial

阿特珠单抗联合贝伐珠单抗和化疗治疗转移性非鳞状非小细胞肺癌:随机双盲3期IMpower151试验

Zhou, Caicun; Dong, Xiaorong; Chen, Gongyan; Wang, Zhehai; Wu, Xianghua; Yao, Yu; Zhang, Yiping; Cheng, Ying; Pan, Hongming; Zhang, Xiaodong; Cui, Jiuwei; Wang, Lifeng; Chen, Xi; Li, Xiaoling; Wang, Ziping; Wang, Qiming; He, Jianxing; Wang, Mengzhao; Yan, Iris; Qian, Li; Xu, Miao; Huang, Xiayu; Sun, Chun; Cai, Jun; Wu, Qiong; Ballinger, Marcus; Kaul, Monika; Srivastava, Minu K

Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial

托瑞普利单抗联合化疗作为广泛期小细胞肺癌的一线治疗:EXTENTORCH III期随机临床试验

Cheng, Ying; Zhang, Wei; Wu, Lin; Zhou, Caicun; Wang, Donglin; Xia, Bing; Bi, Minghong; Fu, Xiuhua; Li, Chong; Lv, Dongqing; Zhao, Yanqiu; Chen, Gongyan; Yi, Tienan; Huang, Jianan; Li, Min; Yang, Runxiang; Huang, Xiaoping; Wang, Ye; Zhang, Mingjun; Pan, Yueyin; Sun, Yilan; Hu, Sheng; Zhang, Xiqin; Zhou, Min; Fang, Jian; Jin, Faguang; Liu, Yunpeng; Li, Yinyin; Zhang, Zhihong; Hu, Jie; Liu, Laiyu; Wang, Rui; Li, Yan; Gu, Kangsheng; Ding, Cuimin; Fan, Qingxia; Zhang, Guojun; Chen, Yongxing; Jiang, Liyan; Zheng, Wei-E; Chen, Shaoshui; Huang, Cheng; Han, Zhigang; Yang, Hong; Wang, Jianfang; Wang, Baocheng; Wu, Huita; Bao, Yongxing; Li, Manxiang; Luo, Xianming; Gu, Shanshan; Yu, Wenbo; Xu, Kai; Zhang, Simo; Yu, Jianjun

Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)

奥莫替尼与吉非替尼治疗未经治疗的 EGFR 突变晚期非小细胞肺癌患者的中枢神经系统疗效:一项随机 III 期试验 (AENEAS) 的数据

Lu, Shun; Dong, Xiaorong; Jian, Hong; Chen, Jianhua; Chen, Gongyan; Sun, Yuping; Ji, Yinghua; Wang, Ziping; Shi, Jianhua; Lu, Junguo; Chen, Shaoshui; Lv, Dongqing; Zhang, Guojun; Liu, Chunling; Li, Juan; Yu, Xinmin; Lin, Zhong; Yu, Zhuang; Wang, Zhehai; Cui, Jiuwei; Xu, Xingxiang; Fang, Jian; Feng, Jifeng; Xu, Zhi; Ma, Rui; Hu, Jie; Yang, Nong; Zhou, Xiangdong; Wu, Xiaohong; Hu, Chengping; Zhang, Zhihong; Lu, You; Hu, Yanping; Jiang, Liyan; Wang, Qiming; Guo, Renhua; Zhou, Jianying; Li, Baolan; Hu, Chunhong; Tong, Wancheng; Zhang, Helong; Ma, Lin; Chen, Yuan; Jie, Zhijun; Yao, Yu; Zhang, Longzhen; Weng, Jie; Li, Weidong; Xiong, Jianping; Ye, Xianwei; Duan, Jianchun; Yang, Haihua; Sun, Meili; Wei, Hongying; Wei, Jiawei; Zhang, Zheyu; Wu, Qiong

Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study

卡瑞利珠单抗联合卡铂和培美曲塞作为晚期非鳞状非小细胞肺癌一线治疗:CameL随机3期研究的5年结果

Zhou, Caicun; Chen, Gongyan; Huang, Yunchao; Zhou, Jianying; Lin, LiZhu; Feng, Jifeng; Wang, Zhehai; Shu, Yongqian; Shi, Jianhua; Hu, Yi; Wang, QiMing; Cheng, Ying; Wu, Fengying; Chen, Jianhua; Lin, Xiaoyan; Wang, Yongsheng; Huang, Jianan; Cui, Jiuwei; Cao, Lejie; Liu, Yunpeng; Zhang, Yiping; Pan, Yueyin; Zhao, Jun; Wang, LiPing; Chang, Jianhua; Chen, Qun; Ren, Xiubao; Zhang, Wei; Fan, Yun; He, Zhiyong; Fang, Jian; Gu, Kangsheng; Dong, XiaoRong; Jin, Faguang; Gao, Hongjun; An, Guangyu; Ding, Cuimin; Jiang, Xiaodong; Xiong, Jianping; Zhou, Xiangdong; Hu, Sheng; Lu, Ping; Liu, Anwen; Guo, Shuliang; Huang, Jianjin; Zhu, Chengchu; Zhao, Jian; Gao, Beili; Chen, Yinglan; Hu, Chengping; Zhang, Jian; Zhang, Hongmei; Zhao, Hui; Wang, Zhigao; Ma, Xinjing; Shi, Wei

Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer

一项针对局部晚期或转移性EGFR突变阳性非小细胞肺癌患者的FURLONG III期研究的患者报告结局,该研究比较了呋莫替尼与吉非替尼作为一线治疗方案的疗效。

Shi, Yuankai; Chen, Gongyan; Wang, Xiang; Liu, Yunpeng; Wu, Lin; Hao, Yanrong; Liu, Chunling; Zhu, Shuyang; Zhang, Xiaodong; Li, Yuping; Liu, Jiwei; Cao, Lejie; Cheng, Ying; Zhao, Hui; Zhang, Shucai; Zang, Aimin; Cui, Jiuwei; Feng, Jian; Yang, Nong; Hu, Jie; Liu, Fei; Jiang, Yong; Ge, Nan

IMpower210: A phase III study of second-line atezolizumab vs. docetaxel in East Asian patients with non-small cell lung cancer

IMpower210:一项针对东亚非小细胞肺癌患者的二线阿特珠单抗与多西他赛的III期研究

Wu, Yi-Long; Lu, Shun; Chen, Gongyan; He, Jianxing; Feng, Jifeng; Zhang, Yiping; Jiang, Liyan; Pan, Hongming; Chang, Jianhua; Fang, Jian; Cai, Amy; Bu, Lilian; Shi, Jane; Xia, Jinjing

Efficacy and safety of utidelone for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer who have failed standard second-line treatment: A phase 2 clinical trial (BG01-1801)

utidelone治疗局部晚期或转移性非小细胞肺癌且标准二线治疗失败患者的疗效和安全性:一项2期临床试验(BG01-1801)

Shi, Yuankai; Chen, Gongyan; Zhao, Yanqiu; Zhao, Jing; Lin, Lin

Third-line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases: A post hoc analysis of ALTER1202, a randomized, double-blind phase 2 study

复发/难治性小细胞肺癌脑转移患者接受三线或以上安罗替尼治疗:一项随机、双盲 II 期研究 ALTER1202 的事后分析

Cheng, Ying; Wang, Qiming; Li, Kai; Shi, Jianhua; Han, Baohui; Wu, Lin; Chen, Gongyan; He, Jianxing; Wang, Jie; Qin, Haifeng; Li, Xiaoling

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

AENEAS:一项随机III期试验,比较奥莫替尼与吉非替尼作为一线疗法治疗伴有EGFR 19号外显子缺失或L858R突变的局部晚期或转移性非小细胞肺癌的疗效

Lu, Shun; Dong, Xiaorong; Jian, Hong; Chen, Jianhua; Chen, Gongyan; Sun, Yuping; Ji, Yinghua; Wang, Ziping; Shi, Jianhua; Lu, Junguo; Chen, Shaoshui; Lv, Dongqing; Zhang, Guojun; Liu, Chunling; Li, Juan; Yu, Xinmin; Lin, Zhong; Yu, Zhuang; Wang, Zhehai; Cui, Jiuwei; Xu, Xingxiang; Fang, Jian; Feng, Jifeng; Xu, Zhi; Ma, Rui; Hu, Jie; Yang, Nong; Zhou, Xiangdong; Wu, Xiaohong; Hu, Chengping; Zhang, Zhihong; Lu, You; Hu, Yanping; Jiang, Liyan; Wang, Qiming; Guo, Renhua; Zhou, Jianying; Li, Baolan; Hu, Chunhong; Tong, Wancheng; Zhang, Helong; Ma, Lin; Chen, Yuan; Jie, Zhijun; Yao, Yu; Zhang, Longzhen; Jie, Weng; Li, Weidong; Xiong, Jianping; Ye, Xianwei; Duan, Jianchun; Yang, Haihua; Sun, Meili; Sun, Changan; Wei, Hongying; Li, Chuan; Ali, Siraj M; Miller, Vincent A; Wu, Qiong